NextCell Pharma
NextCell announces strategic collaboration with Fujifilm Irvine Scientific
In 2024, NextCell expanded its portfolio by developing a research-use-only umbilical cord MSC product, manufactured using proprietary in-house expertise for the commercial market. Building on this progress, the company is now initiating a collaboration with Fujifilm Irvine Scientific Inc. ("Fujifilm") to combine this cell product with Fujifilm's established MSC media and cryopreservation product lines.
Fujifilm is a global leader in the development of high-quality cell culture solutions for the life science and medical markets. With over 50 years of industry experience, Fujifilm is recognised for its innovation and commitment to advancing areas such as cell and gene therapy.
This joint offering is expected to provide researchers and industry stakeholders with:
- Standardised, high-quality MSC reference material
- Optimised media and cryopreservation solutions for MSC culture and cold storage
- A reliable reference system for the development and validation of new therapies
"We have worked closely together to develop this business relationship and are proud to be able to announce this new opportunity to our shareholders," said Dr Lindsay Davies, CSO at NextCell.
Mathias Svahn, CEO at NextCell, added: "This is a new business venture for NextCell, and we are excited to collaborate with Fujifilm, combining our expertise to build a strong partnership for the future."
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-05-2025 09:40 CET.
Datum | 2025-05-20, kl 09:40 |
Källa | Cision |
